Summary & Overview
HCPCS Q4339: Artacent vericlen, Biologic Graft per cm2
HCPCS Level II code Q4339 denotes Artacent vericlen billed per square centimeter as an add-on product to be reported in addition to a primary procedure. As an add-on supply code for a biologic graft or tissue product, it is relevant wherever surgical reconstruction or wound repair requires a surface-applied biologic. Nationwide, this code matters for accurate supply reporting, product utilization tracking, and payer-specific coverage and payment rules.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage considerations and benchmarking context for these payers, as well as the clinical scenarios where the product is typically used. The publication outlines where the code is billed (operative and outpatient surgical settings), how it functions as an add-on to primary procedures, and the implications for coding accuracy and billing compliance.
The report covers national benchmarks and payer policy summaries where available, recent policy or coding updates that affect add-on biologic supply billing, and clinical context describing typical applications of surface-applied biologic materials. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q4339 represents Artacent vericlen, billed per square centimeter as an add-on, list separately in addition to primary procedure. This code indicates a biologic or tissue-based product used in procedural repair or reconstruction where the product is applied by surface area.
Service Type: Product/Implant or Biologic Graft Application
Typical Site of Service: Operative or Ambulatory Surgical Settings, including hospital operating rooms and outpatient surgical centers where primary procedures requiring graft or biologic surface application are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a focal articular cartilage defect of the knee causing persistent pain, swelling, and mechanical symptoms after conservative therapy. The patient is evaluated in an orthopedic clinic and undergoes preoperative imaging (MRI) confirming a symptomatic chondral lesion. During arthroscopic or open cartilage repair, the surgeon applies a biologic, matrix-based cartilage implant (billed as Q4339 per square centimeter, add-on) directly to the debrided defect site. The clinical workflow includes preoperative consent for cartilage repair, intraoperative measurement of defect size in square centimeters to determine units of Q4339, secure fixation of the implant (with fibrin glue or sutures as clinically indicated), routine intraoperative documentation of location and dimensions, and postoperative rehabilitation protocol directed by the orthopedic team. Typical sites of service are hospital outpatient departments or ambulatory surgery centers. Postoperative follow-up visits assess graft integration, range of motion, and progression of weightbearing and physical therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no modifier applies to the service billed with Q4339 |